SR One and M Ventures, which own more than a fifth of shares between them, are in line for exits as Progyny files for an initial public offering on the Nasdaq Global Market.
Progyny, a US-based fertility benefits platform backed by pharmaceutical firms GlaxoSmithKline and Merck Group, filed for a $100m initial public offering on the Nasdaq Global Market on Friday.
The company has not yet set a price range or decided how many shares it will issue.
Progyny was created from the merger of reproductive health technology developers Auxogyn and Fertility Authority in 2015, and provides fertility benefits services to some 1.4 million employees across 80 corporations.
Prospective parents have…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
